{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:26:54Z","timestamp":1790015214573,"version":"4.0.1"},"reference-count":80,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s441359","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:00:14Z","timestamp":1720756814000},"page":"791-810","source":"Crossref","is-referenced-by-count":1,"title":["UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"David","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-7516","authenticated-orcid":true,"given":"Neal","family":"Navani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1065-0467","authenticated-orcid":true,"given":"James","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Wheatstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Allen-Delingpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cicely","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-0902","authenticated-orcid":true,"given":"Khalid","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"key":"ref2","first-page":"1121","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol Cell"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13063-020-4139-0","volume":"21","author":"He","year":"2020","journal-title":"Trials"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41416-021-01689-z","volume":"126","author":"Capobianco","year":"2022","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12910-019-0395-5","volume":"20","author":"Strzebonska","year":"2019","journal-title":"BMC Med Ethics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1185\/03007995.2016.1140027","volume":"32","author":"Shafrin","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","volume":"200","author":"Etekal","year":"2023","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"n2191","DOI":"10.1136\/bmj.n2191","volume":"374","author":"Dawoud","year":"2021","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0272989X21994553","volume":"41","author":"Ciani","year":"2021","journal-title":"Med Decis Making"},{"key":"ref12","unstructured":"Institute for Quality and Efficiency in Health Care. IQWiG Reports \u2013 commission No. A10-05. Validity of surrogate endpoints in oncology; 2011. Available from: https:\/\/www.iqwig.de\/download\/a10-05_executive_summary_v1-1_surrogate_endpoints_in_oncology.pdf. Accessed May 3, 2022."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1002873","DOI":"10.1371\/journal.pmed.1002873","volume":"16","author":"Bruce","year":"2019","journal-title":"PLOS Med"},{"key":"ref15","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies; 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed May 3, 2022."},{"key":"ref16","unstructured":"FDA. PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022; 2022. Available from: https:\/\/www.fda.gov\/media\/99140\/download. Accessed May 3, 2023."},{"key":"ref17","unstructured":"Medicines and Healthcare products Regulatory Agency. Consultation document: MHRA draft guidance on randomised controlled trials generating real-world evidence to support regulatory decisions. GOV.UK; 2021. Available from: https:\/\/www.gov.uk\/government\/consultations\/mhra-draft-guidance-on-randomised-controlled-trials-generating-real-world-evidence-to-support-regulatory-decisions\/consultation-document-mhra-draft-guidance-on-randomised-controlled-trials-generating-real-world-evidence-to-support-regulatory-decisions. Accessed May 3, 2022."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/annonc\/mdw233","volume":"27","author":"Kleijnen","year":"2016","journal-title":"Ann Oncol"},{"key":"ref20","unstructured":"FDA. Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure; 2022. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. Accessed May 3, 2022."},{"key":"ref21","volume-title":"The Evidence Forum","year":"2017"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jval.2019.03.007","volume":"22","author":"Kordecka","year":"2019","journal-title":"Value Health"},{"key":"ref23","unstructured":"Medicines and healthcare products regulatory agency. Guidance: innovative licensing and access pathway. GOV.UK; 2021. Available from: https:\/\/www.gov.uk\/guidance\/innovative-licensing-and-access-pathway. Accessed May 3, 2022."},{"key":"ref24","unstructured":"Scottish Medicines Consortium. March 2022 decisions news release. Scottish Medicines Consortium; 2022. Available from: https:\/\/www.scottishmedicines.org.uk\/about-us\/latest-update\/march-2022-decisions-news-release\/. Accessed March 20, 2024."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","volume":"38","author":"Grigore","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"ref27","unstructured":"NICE. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma; 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ta524\/chapter\/1-Recommendations. Accessed February 20, 2024."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref29","unstructured":"Pan-Canadian oncology drug review. Pertuzumab (Perjeta) NBC \u2013 final recommendation; 2015. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_pertuzumab_perjeta_nbc_fn_rec.pdf. Accessed February 15, 2024."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.896","volume":"25","author":"Rizzello","year":"2022","journal-title":"Value Health"},{"key":"ref31","unstructured":"NICE. NICE health technology evaluations: the manual. Process and methods [PMG36]. Natl Inst Health Care Excell. 2022;2022:181."},{"key":"ref32","unstructured":"NICE. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. Technology appraisal guidance [TA761]; 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ta761\/chapter\/3-Committee-discussion. Accessed June 2, 2022."},{"key":"ref33","unstructured":"NICE. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. Technology appraisal guidance [TA763]; 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ta763\/chapter\/3-Committee-discussion. Accessed June 2, 2022."},{"key":"ref34","unstructured":"Bouvy J How \u2018surrogate outcomes\u2019 influence long-term health outcomes | blogs | news. NICE; 2023. Available from: https:\/\/www.nice.org.uk\/news\/blog\/how-surrogate-outcomes-influence-long-term-health-outcomes. Accessed February 20, 2024."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","volume":"136","author":"Pasalic","year":"2020","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"ref37","unstructured":"IQVIA Institute. Evolving oncology endpoints; 2021. Available from: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/evolving-oncology-endpoints. Accessed May 3, 2022."},{"key":"ref38","unstructured":"EUnetHTA. Endpoints used in relative effectiveness assessment: surrogate endpoints; 2015. Available from: https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/01\/Endpoints-used-in-Relative-Effectiveness-Assessment-Surrogate-Endpoints_Amended-JA1-Guideline_Final-Nov-2015.pdf. Accessed June 27, 2024."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jval.2017.07.011","volume":"21","author":"Hashim","year":"2018","journal-title":"Value Health"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s43441-020-00131-5","volume":"54","author":"Dreyer","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s43441-020-00193-5","volume":"55","author":"LoCasale","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2217\/cer-2020-0228","volume":"10","author":"Jaksa","year":"2021","journal-title":"J Comp Eff Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e0000003","DOI":"10.1371\/journal.pdig.0000003","volume":"1","author":"Zhang","year":"2022","journal-title":"PLOS Digit Health"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/jamia\/ocaa340","volume":"28","author":"Liaw","year":"2021","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"ref46","unstructured":"Friends of Cancer Research. Considerations for use of real-world evidence in oncology: a friends of cancer research white paper; 2020. Available from: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Use_of_Real-World_Evidence_in_Oncology_0.pdf. Accessed May 3, 2023."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1200\/CCI.21.00013","volume":"5","author":"Horvat","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv Ther"},{"key":"ref49","unstructured":"MHRA. MHRA guideline on randomised controlled trials using real-world data to support regulatory decisions. GOV.UK. Available from: https:\/\/www.gov.uk\/government\/publications\/mhra-guidance-on-The-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions\/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions. Accessed May 3, 2022."},{"key":"ref50","unstructured":"NICE. Real-world evidence framework feedback. NICE. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/real-world-evidence-framework-feedback. Accessed May 3, 2022."},{"key":"ref51","unstructured":"Health and Social Care, Health and Care Research Wales, NHS Research Scotland, NHS Health Research Authority. Does my project require review by a Research Ethics Committee? Available from: https:\/\/www.hra-decisiontools.org.uk\/ethics\/docs\/Algorithm%20-%20Does%20my%20project%20require%20REC%20review%20v2.0%2020200304.pdf. Accessed June 4, 2024."},{"key":"ref52","unstructured":"NHS England. National cancer patient experience survey: 2019 survey results. 2019 survey results; 2020. Available from: https:\/\/www.ncpes.co.uk\/2019-survey-results\/. Accessed May 3, 2022."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ajh.26166","volume":"96","author":"Mohyuddin","year":"2021","journal-title":"Am J Hematol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2017.06.025","volume":"83","author":"Hamel","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e200363","DOI":"10.1001\/jamanetworkopen.2020.0363","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Network Open"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/annonc\/mdx265","volume":"28","author":"Zhu","year":"2017","journal-title":"Ann Oncol"},{"key":"ref57","unstructured":"Friends of Cancer Research. Establishing a framework to evaluate real-world endpoints; 2018. Available from: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/RWE_FINAL-7.6.18_1.pdf. Accessed September 21, 2022."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.18.00155","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1186\/s12885-021-08881-7","volume":"21","author":"Atrash","year":"2021","journal-title":"BMC Cancer"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jcm10010105","volume":"10","author":"Akizuki","year":"2020","journal-title":"J Clin Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.clml.2019.06.007","volume":"19","author":"Chari","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"236","DOI":"10.18553\/jmcp.2017.23.2.236","volume":"23","author":"Chen","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e0208507","DOI":"10.1371\/journal.pone.0208507","volume":"13","author":"Remes","year":"2018","journal-title":"PLoS One"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40487-021-00146-4","volume":"9","author":"Rice","year":"2021","journal-title":"Oncol Ther"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e0258487","DOI":"10.1371\/journal.pone.0258487","volume":"16","author":"Szabo","year":"2021","journal-title":"PLoS One"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/14737140.2017.1316196","volume":"17","author":"Fiteni","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11899-019-0497-7","volume":"14","author":"Kothari","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-19-1213","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/cam4.2828","volume":"9","author":"Suzuki","year":"2020","journal-title":"Cancer Med"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.02.031","volume":"149","author":"Provencio","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801851","volume":"11","author":"Charalampous","year":"2022","journal-title":"Front Oncol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2023022540","volume":"143","author":"Kogure","year":"2024","journal-title":"Blood"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref77","doi-asserted-by":"publisher","volume-title":"EHA25 Virtual Abstract Book","year":"2020","DOI":"10.1097\/HS9.0000000000000404"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"Grimwade","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.16971","volume":"191","author":"Smith","year":"2020","journal-title":"Br J Haematol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e108722","DOI":"10.1371\/journal.pone.0108722","volume":"9","author":"Schievink","year":"2014","journal-title":"PLoS One"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=100715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=100715","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:00:33Z","timestamp":1720756833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/uk-stakeholder-perspectives-on-surrogate-endpoints-in-cancer-and-the-p-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":80,"URL":"https:\/\/doi.org\/10.2147\/cmar.s441359","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}